Keryx Biopharmaceuticals Announces Recent Business Progress

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
297
Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference
  • Enters 2017 with positive momentum for Auryxia® (ferric citrate) in dialysis; preliminary unaudited fourth quarter net U.S. product sales of $8.2 million
  • Submitted supplemental new drug application (sNDA) seeking Auryxia label expansion to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease
  • Expands management’s operational and strategic expertise with the appointment of two executives 

SAN FRANCISCO, Jan. 08, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced its recent business progress and reviewed its corporate strategy to drive continued growth. Greg Madison, Keryx’s chief executive officer, will review this progress as part of a live webcast of the company’s corporate presentation at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11 at 2:30 p.m. PST (5:30 p.m. EST).

“As we enter 2017, with the successful return of Auryxia to dialysis patients in November and the potential approval and launch of this medicine in iron deficiency anemia, non-dialysis dependent chronic kidney disease, we believe we are well positioned for growth,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “The potential expanded indication would enable us to leverage our commercial infrastructure and significantly increase the number of people that can potentially be treated with Auryxia.”

Business Progress Keryx is making important progress toward achieving its vision to become a leading renal company. It has generated momentum since the resupply of Auryxia for the treatment of hyperphosphatemia in adults with chronic kidney disease (CKD) on dialysis. In addition, the potential approval of ferric citrate in late 2017 for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD) CKD may be a significant near-term milestone. The section below announces the company’s recent progress toward achieving its vision and selected preliminary unaudited fourth quarter and year-end 2016 financial results.

Auryxia Commercial Progress

  • The company reported prescription demand for the fourth quarter of 2016 was approximately 8,700 prescriptions, which included approximately 4,500 prescriptions for the month of December, the first full month of sales post resupply of Auryxia. This compares to approximately 5,000 prescriptions for the month of July 2016, the last full month of sales prior to the previously announced supply interruption. 
  • Today, Keryx announced that the U.S. Food and Drug Administration (FDA) has approved Patheon’s manufacturing facility in France to manufacturer supply of Auryxia for the U.S. The approval of this site provides Keryx with a third manufacturing site for finished Auryxia drug product and provides a redundant source to help ensure continuous supply of this medicine.

Potential Label Expansion Opportunity

  • The company announced that the sNDA for Auryxia has been submitted to the FDA seeking label expansion to include the treatment of IDA in adults with NDD-CKD. The company will outline its commercial plan for Auryxia, should it be approved for this expanded indication, while attending the J.P. Morgan Healthcare conference.
  • Keryx also announced that detailed results from its pivotal Phase 3 trial that evaluated ferric citrate for the treatment of IDA in adults with stage 3 - 5 NDD-CKD has been submitted for publication in a peer-reviewed scientific journal. Publication of the data is a key component of the company’s strategy to advance understanding of the potential importance of Auryxia to treat this difficult disease.
  • Abstracts related to clinical trials evaluating IDA, NDD-CKD have been accepted for presentation at the International Society of Nephrology (ISN) World Congress of Nephrology (WCN) in April 2017, a global not-for-profit society dedicated to improving kidney care and reducing the incidence and impact of kidney disease worldwide.

Two New Executive Team Appointments Today, the company announced that it has appointed Christine Carberry as chief operating officer and Melissa Bradford-Klug as chief business officer, both will report to Greg Madison. Ms. Carberry will start on January 16, 2017 and be responsible for driving a stronger focus on operational excellence and execution. Ms. Bradford-Klug started on January 3, 2017 and is responsible for business development, corporate strategy and alliance management for the company.

Ms. Carberry brings to Keryx approximately 30 years of biotech and pharmaceutical leadership, including most recently as an executive team member and senior vice president, quality, technical operations, program and alliance management at Forum Pharmaceuticals. Prior to Forum, Ms. Carberry spent 25 years at Biogen and held roles of increasing responsibility, culminating as vice president, program and alliance management. She brings operational excellence in technical operations and strategic development, including research, development and lifecycle management for commercial medicines.

Ms. Bradford-Klug brings to Keryx more than 17 years of senior strategic planning and business development experience in the life sciences industry. Ms. Bradford-Klug joins Keryx most recently from AMAG Pharmaceuticals where she served as senior vice president of business development and completed multiple value adding transactions. Prior to AMAG, she held leadership roles with Mallinckrodt Pharmaceuticals, Baxter International and Eli Lilly and Company.

Mr. Madison added, “I am thrilled to have Christine and Melissa join our management team during this important time in the evolution of our organization. With their appointments, we believe we have the depth of expertise and the bandwidth to manage the business operations while simultaneously seeking to build a leading renal company. Our entire organization is excited to maximize the potential we have with Auryxia and execute our strategic plan and we welcome Christine and Melissa who will be instrumental in achieving our vision.”

Preliminary Unaudited Financial Data Total revenues for the quarter ended December 31, 2016 are expected to be approximately $9.5 million, compared with $5.8 million during the same period in 2015. Total revenue expectations for the fourth quarter of 2016 consist of approximately $8.2 million in ex-factory Auryxia net U.S. product sales, compared to $4.8 million in the fourth quarter of 2015, which were recorded based on actual prescriptions written during the period. Total expected revenue for the fourth quarter of 2016 also include $1.3 million in license revenues as compared to $1.0 million during the same period in 2015.

For the year ended 2016, total revenues are expected to be approximately $31.9 million as compared to $13.7 million in 2015. Total expected revenues for 2016 include $27.1 million of Auryxia net U.S. product sales and $4.8 million in license revenues as compared to $10.1 million and $3.5 million, respectively in 2015.

Cost of goods sold for the quarter ended December 31, 2016 are expected to be approximately $13.3 million, compared with $1.1 million during the same period in 2015. Expected cost of goods sold for the fourth quarter of 2016 include an approximately $11.8 million write-off of work-in-process inventory that was determined to no longer be suitable for commercial manufacture. For the year ended 2016, total cost of goods sold are expected to be approximately $37.7 million, as compared to $4.5 million in 2015. Total expected 2016 cost of goods includes approximately $25.6 million in write-offs of work-in-process inventory that was determined to no longer be suitable for commercial manufacture and approximately $2.6 million related to manufacturing charges incurred as a result of not fully utilizing planned production at the company’s third-party drug product manufacturers. Total 2015 cost of goods sold included $2.6 million related to manufacturing charges incurred as a result of not fully utilizing planned production at the company’s third-party drug product manufacturers.

Cash and cash equivalents as of December 31, 2016 totaled approximately $112.1 million.

The preliminary unaudited financial data for the quarter and the year ended December 31, 2016 set forth above is derived from preliminary internal financial reports. Keryx has not yet finalized its complete results of operations for the year ended December 31, 2016.  In connection with the finalization of its year-end closing and reporting processes, the completion of its financial statements for the year ended December 31, 2016 and the completion of the audit of its financial statements for the year ended December 31, 2016, Keryx and its auditors may identify items that would require Keryx to make adjustments, some of which could be material, to the preliminary unaudited financial data set forth above.

Webcast Keryx will webcast its corporate presentation and breakout session at the 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 2:30 p.m. PST (5:30 p.m. EST). A link to the live webcast is available via Keryx’s website, www.keryx.com , in the Webcasts and Presentations section. An archived version of the presentation will be available on Keryx’s website for 15 days following conclusion of the live presentation.

About Iron Deficiency Anemia, NDD-CKD Iron deficiency anemia is a common complication in patients with non-dialysis dependent chronic kidney disease (NDD-CKD), and the prevalence and severity of IDA increases as kidney disease progresses. It is estimated that there are approximately 1.6 million people living in the U.S. with stage 3-5 non-dialysis dependent chronic kidney disease and iron deficiency anemia. Efficacy and tolerability of current oral iron supplements are mixed. Intravenous (IV) iron administration is associated with important risks and burdens.

About Auryxia Auryxia (ferric citrate) was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with CKD on dialysis. The U.S. approval of Auryxia was based on data from the company's Phase 3 registration program in dialysis patients. In the Phase 3 clinical trials, Auryxia effectively reduced serum phosphorus levels to within the KDOQI guidelines range of 3.5 to 5.5 mg/dL.

Auryxia binds with dietary phosphate in the GI tract and precipitates as ferric phosphate. The unbound portion of Auryxia has been shown to increase serum iron parameters including ferritin and transferrin saturation (TSAT). Iron absorption from Auryxia may lead to excessive elevations in iron stores. Accordingly, physicians should assess and monitor iron parameters before starting and while on Auryxia, and may need to decrease or discontinue IV iron for these patients. The most common adverse events for Auryxia treated patients were gastrointestinal related, including diarrhea, nausea, vomiting and constipation. For more information about Auryxia and the U.S. full prescribing information, visit www.Auryxia.com .

Use of ferric citrate in patients with NDD-CKD and IDA, as highlighted above, is investigational and has not been determined to be safe or efficacious.

IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric citrate) Contraindication:  Patients with iron overload syndrome, e.g. hemochromatosis, should not take Auryxia®.

Iron Overload:  Iron absorption from Auryxia may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Auryxia. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

Accidental Overdose of Iron:  Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep Auryxia away from children as it contains iron. Call a poison control center or your physician in case of an accidental overdose in a child.

Patients with Gastrointestinal Bleeding or Inflammation:  Safety has not been established for these patients.

Adverse Events:  The most common adverse events with Auryxia were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%). Auryxia contains iron and may cause dark stools, which is considered normal with oral medications containing iron.

Drug Interactions:  Doxycycline should be taken at least 1 hour before Auryxia. Ciprofloxacin should be taken at least 2 hours before or after Auryxia.

For Full Prescribing Information for Auryxia, please visit  http://auryxia.com/important-safety-information/

Forward Looking Statements Some of the statements included in this press release, particularly those regarding expected revenues and expenses,  the commercialization and ongoing clinical development of Auryxia and the expected impact of the new members of management, including those statements related to Preliminary Unaudited Year-end Financial Data and the submission of an sNDA to the FDA to expand the label of ferric citrate to include the treatment of IDA in adults with stage 3-5 NDD-CKD and the potential approval in this indication and the impact thereof on Keryx, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: the completion of our financial statements for the year ended December 31, 2016 and the audit thereof; whether we can increase adoption of Auryxia in patients with CKD on dialysis; whether we can maintain our operating expenses to projected levels while continuing our current clinical, regulatory and commercial activities; whether we will able to identify and negotiate acceptable terms with a commercialization partner in the E.U.; whether we or a partner can successfully launch Fexeric® in the E.U.; whether Riona® will be successfully marketed in Japan by our Japanese partner, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd; the risk that the FDA may not concur with our interpretation of our Phase 3 study results in NDD- CKD, supportive data, conduct of the studies, or any other part of our regulatory submission and could ultimately deny approval of ferric citrate for the treatment of IDA in adults with stage 3-5 NDD-CKD; the risk that if approved for use in NDD-CKD that we may not be able to successfully market Auryxia for use in this indication; our ability to continue to supply Auryxia following the recent resupply to the market; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at  http://www.keryx.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate), an iron-based phosphate binder, in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including evaluation of iron deficiency anemia in adults with non-dialysis depended chronic kidney disease and in-licensing medicines for renal disease. For more information about Keryx, please visit  www.keryx.com .

KERYX BIOPHARMACEUTICALS CONTACTS: Amy Sullivan Vice President, Corporate Affairs T: 617.466.3519 amy.sullivan@keryx.com Lora Pike Senior Director, Investor Relations T: 617.466.3511 lora.pike@keryx.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 143

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 45

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 116

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 35

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 10

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading

Top 5 Most Recently Viewed Articles

U.S. Industrial Production Unexpectedly Declines, Impacting Growth

Updated Category News Views 62

U.S. Industrial Production Experiences a Notable Decline The latest report reveals that U.S. industrial production has faced an unexpected decline, recorded at -0.3%. This drop highlights the ongoing struggles within the manufacturing, mining, and utility sectors. Disappointing Performance Against Expectations When comparing the -0.3% figure to a predicted decrease of...

Continue Reading
MAXHUB Partners with Microsoft to Enhance Teams Rooms Experience

Updated Category News Views 363

MAXHUB Collaborates with Microsoft to Enhance Teams In an exciting development within the tech landscape, MAXHUB is teaming up with Microsoft in an initiative aimed at improving the security and reliability of Microsoft Teams Rooms. This partnership aligns with MAXHUB's vision of leading in integrated commercial display and unified communications solutions, providing...

Continue Reading
US Dollar Strengthens While Global Markets Face Turmoil

Updated Category News Views 486

US Dollar's Rise Amid Trade Tensions In an unexpected turn of events, the US dollar has extended its gains following President Trump's announcement of new tariffs. As the global markets react to these developments, we dive into the implications for various economies and asset classes. The latest updates indicate that the 25% tariffs on imports from Canada and Mexico,...

Continue Reading
Understanding Your Rights as a Perrigo Company Shareholder

Updated Category News Views 135

Understanding Your Rights as a Perrigo Company Shareholder Shareholders of Perrigo Company plc (NYSE: PRGO) should stay informed about recent developments regarding potential securities law violations. The underlying issues stem from allegations that the company misled investors regarding its infant formula business, which has drawn significant scrutiny. Allegations...

Continue Reading
Spring Surprises: White Castle Unveils Exciting Deals Ahead

Updated Category News Views 521

Spring Promotions at White Castle As the season transforms, White Castle, the pioneering fast-food restaurant known for its Original Slider, unveils enticing deals for its loyal customers. Embracing longer days and warmer weather, the company is determined to deliver exceptional savings for all cravings this spring. Celebrating with Value-Driven Offers White Castle is...

Continue Reading